Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
US10525083B2 · kind B2 · utility
9Cited by
55References
33Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 6, 2017 |
| Grant date | Jan 7, 2020 |
| Priority date | — |
| Expiry date | Oct 6, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.